INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,273,417 | +38.0% | 338,372 | -17.7% | 0.00% | – |
| Q2 2023 | $4,544,753 | -18.2% | 410,918 | -0.7% | 0.00% | – |
| Q1 2023 | $5,555,441 | -41.5% | 413,659 | -46.1% | 0.00% | -100.0% |
| Q4 2022 | $9,490,623 | -25.7% | 767,229 | -16.2% | 0.00% | -66.7% |
| Q3 2022 | $12,777,000 | +150.5% | 915,961 | +148.0% | 0.00% | +200.0% |
| Q2 2022 | $5,101,000 | -10.2% | 369,384 | +5.8% | 0.00% | -50.0% |
| Q1 2022 | $5,681,000 | -5.7% | 349,131 | -5.6% | 0.00% | 0.0% |
| Q4 2021 | $6,026,000 | +23.5% | 369,884 | +12.6% | 0.00% | +100.0% |
| Q3 2021 | $4,878,000 | -25.0% | 328,419 | +0.8% | 0.00% | 0.0% |
| Q2 2021 | $6,507,000 | -70.6% | 325,816 | -66.0% | 0.00% | -83.3% |
| Q1 2021 | $22,108,000 | +54.2% | 957,828 | +65.0% | 0.01% | +100.0% |
| Q4 2020 | $14,334,000 | -23.8% | 580,339 | +27.9% | 0.00% | -40.0% |
| Q3 2020 | $18,806,000 | -29.3% | 453,590 | -18.4% | 0.01% | -50.0% |
| Q2 2020 | $26,618,000 | -0.3% | 555,585 | +31.0% | 0.01% | -16.7% |
| Q1 2020 | $26,709,000 | -74.9% | 424,228 | -50.6% | 0.01% | -73.9% |
| Q4 2019 | $106,523,000 | +48.3% | 859,612 | -20.6% | 0.05% | +35.3% |
| Q3 2019 | $71,848,000 | -22.9% | 1,082,693 | -7.6% | 0.03% | -20.9% |
| Q2 2019 | $93,241,000 | -38.8% | 1,171,821 | -13.9% | 0.04% | -43.4% |
| Q1 2019 | $152,292,000 | +253.5% | 1,361,448 | +218.5% | 0.08% | +216.7% |
| Q4 2018 | $43,081,000 | +10.0% | 427,435 | +38.0% | 0.02% | +41.2% |
| Q3 2018 | $39,152,000 | -37.4% | 309,843 | -58.4% | 0.02% | -43.3% |
| Q2 2018 | $62,558,000 | +763.8% | 745,521 | +533.2% | 0.03% | +900.0% |
| Q1 2018 | $7,242,000 | -33.8% | 117,730 | -37.1% | 0.00% | -50.0% |
| Q4 2017 | $10,942,000 | -23.0% | 187,300 | -23.5% | 0.01% | -45.5% |
| Q3 2017 | $14,208,000 | -81.2% | 244,805 | -60.8% | 0.01% | -82.8% |
| Q2 2017 | $75,597,000 | -1.5% | 624,396 | -8.0% | 0.06% | -8.6% |
| Q1 2017 | $76,745,000 | +454.0% | 678,553 | +432.2% | 0.07% | +400.0% |
| Q4 2016 | $13,853,000 | -83.6% | 127,506 | -75.2% | 0.01% | -83.7% |
| Q3 2016 | $84,699,000 | +9806.3% | 514,605 | +8485.3% | 0.09% | +8500.0% |
| Q2 2016 | $855,000 | -91.8% | 5,994 | -92.6% | 0.00% | -92.3% |
| Q1 2016 | $10,399,000 | +1067.1% | 80,942 | +1406.7% | 0.01% | +1200.0% |
| Q3 2015 | $891,000 | +44.2% | 5,372 | +109.8% | 0.00% | 0.0% |
| Q2 2015 | $618,000 | -97.9% | 2,561 | -97.5% | 0.00% | -96.4% |
| Q1 2015 | $29,179,000 | +6369.8% | 103,463 | +3480.0% | 0.03% | – |
| Q4 2014 | $451,000 | -85.4% | 2,890 | -77.8% | 0.00% | -100.0% |
| Q3 2014 | $3,085,000 | +575.1% | 13,034 | +574.6% | 0.00% | +200.0% |
| Q2 2014 | $457,000 | -87.9% | 1,932 | -83.2% | 0.00% | -75.0% |
| Q1 2014 | $3,784,000 | – | 11,474 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |